THE WIRE · № 74854
Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn's Disease and Ulcerative Colitis at ACG 2026
01 THE MACHINE READ
WHY IT MATTERS.
Clinical data presentations can support future label expansion and prescribing, but no revenue or pricing figures are given.
Incremental IBD data, no market-moving numbers disclosed
Peer reaction and any regulatory filing follow-up
No efficacy magnitude or sales guidance given
FULL DISPATCH
New data show favorable outcomes with subcutaneous infliximab following intravenous infliximab interruption, regardless of prior antibody status, in adult patients with moderate to severely active Crohn's disease and ulcerative colitis Late-breaking analysis shows significantly higher...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
Humana surges after topping 2027 Medicare star ratings2026-10-09 18:15 UTC
First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer2026-10-10 04:41 UTC
Oura Smart Ring Wants $2 Billion From Its IPO. Original Medicare Still Pays $0 for the Health-Tracking Gear2026-10-10 14:00 UTC
How de-extincting dire wolves and woolly mammoths may extend human life2026-10-10 14:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.